Merck Healthcare KGaA logo

Principal Scientist, Translational Biology, LNP Discovery

Merck Healthcare KGaA

Billerica, MAOnsitePosted 1 day ago$126,900 - $215,400/year
Full TimeSenior LevelResearch & ScientistPharmaceutical
Original posting ↗

Summary

The Translational Biologist (Principal Scientist), LNP Discovery Biology is a scientific and cross-functional role responsible for defining and executing in vivo biology translational strategies for LNP delivery programs within Research Unit Neuroscience & Immunology (N&I). With a particular focus on the design, management, and interpretation of non-human primate (NHP) studies, the role characterizes the profile of differentiated, targeted LNP candidates. The role works closely with formulation/CMC, protein engineering, analytical, toxicology, and translational teams.

Job description

Your Role

The Translational Biologist (Principal Scientist), LNP Discovery Biology is a scientific and cross-functional role responsible for defining and executing in vivo biology translational strategies for LNP delivery programs within Research Unit Neuroscience & Immunology (N&I). With a particular focus on the design, management, and interpretation of non-human primate (NHP) studies, the role characterizes the profile of differentiated, targeted LNP candidates. The role works closely with formulation/CMC, protein engineering, analytical, toxicology, and translational teams.

What you will do

  • Define and own the in vivo strategy for LNP discovery disease biology for programs, covering target-cell-directed delivery, pharmacology, dose selection, tolerability and safety, candidate nomination, and IND-enabling planning.
  • Lead NHP study design and provide scientific oversight throughout study execution, including model and species rationale, study objectives, group structure, dose levels, route and schedule, recovery periods, sample-collection cadence, and fit-for-purpose endpoint panels.
  • Oversee CRO and partner-site delivery of NHP studies: scope and review protocols, align operational plans and data standards, monitor timelines and data quality, resolve deviations, and ensure animal-welfare and IACUC/ethics requirements are addressed.
  • Define and interpret integrated pharmacology and safety assessments, including clinical observations, body weight, clinical pathology (hematology, clinical chemistry, and coagulation), cytokines, complement activation, immunogenicity, PK/exposure, biodistribution, and tissue pathology as appropriate.
  • Integrate safety, exposure, biodistribution, and pharmacology data to identify LNP-related risks, assess dose margins, recommend mitigation strategies, and drive evidence-based go/no-go and candidate-selection decisions.
  • Partner with formulation, lipid chemistry, targeting-ligand, and protein-engineering teams to translate in vitro potency, selectivity, and developability data into NHP study designs that discriminate among candidates.
  • Review head-to-head comparisons against internal, commercial, and published benchmarks, clearly explaining study design differences and readouts coming from the study.
  • Author and review study protocols and reports; present data and recommendations to leadership, partners, and advisors as programs mature.

Minimum Qualifications

  • PhD or similar degree in pharmacology, toxicology, immunology, cell biology, molecular biology, or a related discipline.
  • 8+ years of post-PhD experience in biotech, pharma, or an equivalent translational academic setting, including at least 4 years independently leading in vivo programs and NHP studies.

Preferred Qualifications

  • Demonstrated expertise planning, managing, and interpreting NHP studies, including CRO oversight, protocol development, dose and regimen selection, sampling strategies, and study-quality and data review.
  • Strong experience evaluating nonclinical safety and tolerability and integrating clinical observations, clinical pathology, cytokine and complement responses, immunogenicity, exposure, and tissue findings; able to distinguish modality-related signals from study or assay artifacts.
  • Experience supporting candidate selection and/or IND-enabling development; familiarity with GLP study conduct and nonclinical regulatory expectations.
  • Direct experience with GLP NHP studies is strongly preferred.
  • Working knowledge of LNP biology and delivery, including biodistribution, PK/PD, and immune responses; experience with LNPs or other nucleic-acid delivery platforms is highly desirable.
  • Practical understanding of bioanalytical methods used in in vivo studies, such as flow cytometry and molecular or ligand-binding assays, and of fit-for-purpose assay performance and limitations.
  • Evidence of scientific leadership through first- or senior-author publications, patents, or programs with clear personal ownership; demonstrated success influencing cross-functional or global project teams without formal authority.
  • Clear written and verbal communication; able to present study plans, data, risks, and recommendations to leadership, partners, and advisors.

Requirements

  • PhD or similar degree in pharmacology, toxicology, immunology, cell biology, molecular biology, or a related discipline
  • 8+ years of post-PhD experience in biotech, pharma, or equivalent translational academic setting
  • At least 4 years independently leading in vivo programs and NHP studies
  • Expertise planning, managing, and interpreting NHP studies including CRO oversight
  • Experience evaluating nonclinical safety and tolerability
  • Experience supporting candidate selection and/or IND-enabling development
  • Familiarity with GLP study conduct and nonclinical regulatory expectations
  • Working knowledge of LNP biology and delivery including biodistribution, PK/PD, and immune responses
  • Practical understanding of bioanalytical methods such as flow cytometry and ligand-binding assays
  • Evidence of scientific leadership through publications, patents, or programs
  • Clear written and verbal communication

Benefits

  • Health Insurance
  • Paid Time Off (PTO)
  • Retirement Contributions
  • Performance-Based Bonuses

Company overview

Merck Healthcare KGaA is the healthcare business sector of the Merck Group, a German multinational science and technology company headquartered in Darmstadt. Founded in 1668, Merck is the world's oldest operating pharmaceutical and chemical company. The Healthcare division focuses on developing innovative therapies across multiple therapeutic areas including oncology, neurology & immunology, fertility, and cardiovascular, metabolic, and endocrinological disorders. With approximately 62,557 employees globally, Merck Healthcare operates in more than 65 countries and generated 40% of the Group's sales in 2024. The company's oncology portfolio includes blockbuster products like Erbitux (cetuximab) for colorectal and head and neck cancers, Bavencio (avelumab) for urothelial carcinoma, and Tepmetko (tepotinib) for MET-altered cancers. In neurology, Mavenclad (cladribine) has achieved blockbuster status for treating relapsing multiple sclerosis, while the fertility division has helped bring over 6 million babies into the world through products like Gonal-f. Merck Healthcare combines a strong established business with specialty innovation, delivering a diversified portfolio of therapies to millions of patients worldwide.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.